News and Events
James Cloyd has been selected to receive the Sumner J. Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics by the Pediatric Pharmacy Advocacy Group.
Established in 2002 in honor of the late Dr. Sumner Yaffe, the award is given annually in recognition of significant and sustained contributions toward the improvement of children's health through the field of pediatric pharmacology and therapeutics.
A new formulation for a University of Minnesota-developed drug targeted at rare disorders is under development, with the potential to help a small number of Americans each year. The new drug formulation is designed to prevent serious complications that can occur when drug delivery is interrupted.
Nearly 30 million people in the United States suffer from conditions classified as “rare diseases” – defined by the Food and Drug Administration (FDA) as conditions affecting fewer than 200,000 people.
While some bear names you’ve likely never heard of, other examples may surprise you. Huntington’s disease, Tourette’s syndrome and muscular dystrophy are all classified as rare diseases. In all, more than 6,000 medical disorders are considered rare.